Table 5.

Results in perspective (adapted from [24])

	RAS blocking agent	Control	Number of patients	Follow-up	RR (95%CI)
SOLVD [36]	Enalapril	Placebo	4,228	3.4	0.26 (0.13-0.53)
AASK [30]	Ramipril	Betablocker/ Amlodipine	1,094	4.1	0.64 (0.45-0.90)
HOPE [31]	Ramipril	Placebo	9,297	5	0.67 (0.52-0.85)
ANBP2 [37,38]	Enalapril	Diuretic	6,083	4.1	0.70 (0.56-0.86)
ALLHAT [39]	Lisinopril	Chlorthalidone/Amlodipine	33,357	4.9	0.75 (0.59-0.94)
IMAGINE [40]	Quinapril	Placebo	2,553	2.95	0.79 (0.48-1.29)
ADaPT [22]	Ramipril	Betablockers/ Diuretic	2,011	3	0.83 (0.65-0.80)
PEACE [41]	Trandolapril	Placebo	8,290	4.8	0.85 (0.74-0.97)
CAPPP [42]	Captopril	Betablockers/ Diuretic	10,985	6.1	0.89 (0.78-1.03)
DREAM [1,32]	Ramipril	Placebo	5,269	3	0.93 (0.82-1.04)
STOP-2 [43]	Enalapril/ Lisinopril	Betablockers/ Diuretic	6,614	5	0.95 (0.72-1.26)
ALPINE [44]	Candesartan	HCTZ	392	1	0.13 (0.02-0.99)
CASE-J [45]	Candesartan	Amlodipine	4,703	3.2	0.65 (0.44-0.98)
LIFE [46]	Losartan	Atenolol	9,193	4.8	0.75 (0.64-0.88)
CHARM [47]	Candesartan	Placebo	7,599	3.2	0.81 (0.66-0.99)
SCOPE [48]	Candesartan	Placebo	4,937	3.7	0.81 (0.62-1.06)
VALUE [16]	Valsartan	Amlodipine	15,245	4.2	0.81 (0.74-0.89)
PRoFESS [49]	Telmisartan	Placebo	20,332	2.5	0.83 (0.65-1.04)
TRANSCEND [50]	Telmisartan	Placebo	5,926	4.6	0.86 (0.72-1.02)
NAVIGATOR [17]	Valsartan	Placeno	9,306	5	0.86 (0.80-0.92)

Legend. RR, relative risk; HCTZ, hydrochlorothiazide